Skip to main content
Clinical Trials/CTRI/2021/03/032056
CTRI/2021/03/032056
Recruiting
Phase 3

Assessment of inflammatory markers in patients with respiratory illness and the role of cardamom extract and 1-8 cineol in controlling associated inflammation

Zum Heilen Diagnostic Therapeutics ZH DT0 sites0 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: J208- Acute bronchitis due to other specified organisms
Sponsor
Zum Heilen Diagnostic Therapeutics ZH DT
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Zum Heilen Diagnostic Therapeutics ZH DT

Eligibility Criteria

Inclusion Criteria

  • 1\.Age group 19 â?? 70 yrs
  • 2\.Subjects of both male and females involved
  • 3\.Patients with acute respiratory infections
  • 4\.Subjects who are willing to provide written consent for the study
  • 5\.Mild to Moderately severe disease (NEWS score Less than/equal to 8\)
  • 6\.Can take oral medicines
  • 7\.Subject willing to abide by and comply with the study protocol

Exclusion Criteria

  • 1\.Subjects less than 17 years and above 70yrs old
  • 2\.Pregnancy and lactation
  • 3\.Patients with existing history of other inflammatory disease conditions
  • 4\.Patients currently taking anti\-inflammatory drugs and
  • 5\.Immune\-compromised subjects
  • 6\.Severe or complicated lung disease/infection
  • 7\.Presence of acute hypoxic respiratory failure/ need for Intensive care unit (ICU) stay/ Patients who need mechanical ventilation.
  • 8\.Any uncontrolled systemic disease, infection
  • 9\.Those with serious Cardiovascular, Cerebrovascular, Respiratory, Liver or Renal disease or any other disorder.
  • 10\.Other conditions, which in the opinion of the investigators makes the patient unsuitable for enrolment or could interfere in adherence to of the study protocol

Outcomes

Primary Outcomes

Not specified

Similar Trials